A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Trial Profile

A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2017 According to a Teva Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved AirDuoTM RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick (fluticasone propionate inhalation powder) for adolescent and adult patients with asthma.
    • 07 Nov 2016 According to a Teva Pharmaceuticals media release, data from this trial will be presented at the 2016 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top